NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/08/2022
Voltar para busca
Dado oficial do USPTO
P HLA PROTEIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
02/06/2023
Tipo de marca
Mista
Classes Nice
1, 5, 42, 44
Data de depósito
13/10/2020
Data de registro
23/08/2022
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/08/2022
Última transação
02/06/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
04/01/2021
Primeiro uso no comércio
04/01/2021
Código do desenho
3
Tipo de titular
16
Localização do titular
Austin, TX
Examinador
MANGUBAT, ALEXANDER GEORGE
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a square on top with two squares on each side touching corners with one square on the bottom with the top left section missing and a floating square in the middle of the four squares forming the letter "P" next to the literal word "HLA Protein".
Titulares e representantes
Titulares
Pure Protein L.L.C.
Representantes
Ian W. Gillies KNOBBE, MARTENS, OLSON & BEAR, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Reagents for scientificpharmaceuticalclinicalmedical research purposes; laboratory chemicalsprotein-based reagents used for the detection of antibodies and receptors in cellbloodtissue analysis for in vitro diagnostics for scientific use and research in the field of therapeutic reagent designs; chemicals and biochemicals in the nature of reactants and reagents for in vitro scientific or research use; chemicals and biochemicals for use in the manufacture of pharmaceutical preparations; chemicalbiochemical and biotechnological solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with antibody and B or T cell detectionseparation and labelling; biochemical reagents for detecting and analyzing molecules in protein arrays; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; chemicalbiochemical and biotechnological products in the nature of reactants and reagents for use in biotechnological product development of therapeutics for the prevention and treatment of cancerinfectious diseasesautoimmune diseases and allergies; chemicalbiochemical and biotechnological preparations used in industry and sciencein the development and manufacture of pharmaceuticalspharmaceutical preparations and substancesfor the prevention and treatment of cancerinfectious diseasesautoimmune diseases and allergies; chemicalbiochemical and biotechnological preparations used in industry and sciencein the development and manufacture of pharmaceuticalspharmaceutical preparations and substancesfor the detectionprevention and treatment of rejection causing antibodiesB and T cells
Classe 5
Chemicals and biochemicals for in vitro clinical and medical use
Classe 42
Providing scientificpharmaceuticalclinicalmedical research information via the internet; research and development of new products; pharmaceutical drug and biomarker preparation target discoverydevelopmentvalidation in the nature of researchdevelopmentquality assurance services; pharmaceutical and scientific research and development services; medical research services; medical development services in the fields of pharmaceuticalsbiologychemistrybiochemistrybiotechnologyclinical trials; clinical research services in the fields of pharmaceuticalsbiologychemistrybiochemistryclinical trials; clinical development services in the nature of scientific development of clinical trials; consulting services in the field of pharmaceutical assessment; scientific and medical research consulting services for transplant and organ rejection assessment; validation in the nature of quality assurance servicesscreening and mapping in the nature of scientific research and development of biological material for drug discovery and vaccine manufacturing purposes; providing scientific information and medical research information in the fields of pharmaceuticalsbiologychemistrybiochemistrybiotechnologyclinical trials; scientific and medical research and development in the field of cancerinfectious diseasesautoimmune diseases and allergies; scientific and medical research and development in the field of antibodyB cell and T cell detection in transplant and organ rejection
Classe 44
Medical consulting services for transplant and organ rejection assessment
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
23/08/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16/07/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/07/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
23/06/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/06/2022
IUAF
USE AMENDMENT FILED
03/06/2022
EISU
TEAS STATEMENT OF USE RECEIVED
03/06/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/05/2022
EX1G
SOU EXTENSION 1 GRANTED
29/04/2022
EXT1
SOU EXTENSION 1 FILED
29/04/2022
EEXT
SOU TEAS EXTENSION RECEIVED
29/04/2022
DOCK
ASSIGNED TO EXAMINER
25/02/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/09/2021
PUBO
PUBLISHED FOR OPPOSITION
07/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/03/2021
GNRT
NON-FINAL ACTION E-MAILED
29/03/2021
CNRT
NON-FINAL ACTION WRITTEN
29/03/2021
DOCK
ASSIGNED TO EXAMINER
11/03/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2020
NWAP
NEW APPLICATION ENTERED
16/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace P HLA PROTEIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.